EGF and hemophilia A: Four years later, in 2018, emicizumab (HemlibraTM), which targets clotting factors IXa and X, was approved for hemophilia A. Finally, in 2021, amivantamab-vmjw (RybrevantTM), which targets epidermal growth factor and MET receptors, received authorization for the treatment of cancer.